Silver Book Fact

Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.

Gunther, Weigert, Semira Kaya, Berthold Pemp, Stefan Sacu, Michael Lasta, Rene Marcel Werkmeister, Nikolaus Dragostinoff, Christian Simader, Gerhard Garhofer, Ursula Schmidt-Erfurth, and Leopold Shcmetterer. Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. October 2011; 52(11): 8174-8. http://www.iovs.org/content/52/11/8174.abstract

Reference

Title
Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
October 2011
Authors
Gunther, Weigert, Semira Kaya, Berthold Pemp, Stefan Sacu, Michael Lasta, Rene Marcel Werkmeister, Nikolaus Dragostinoff, Christian Simader, Gerhard Garhofer, Ursula Schmidt-Erfurth, and Leopold Shcmetterer
Volume & Issue
Volume 52, Issue 11
Pages
8174-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.  
  • AMD risk reduction through diet
    A recent study indicated that 20% of AMD cases in the AREDS study would have been eliminated if the participants consumed diets with a dGI (dietary glycemic index) below the…  
  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…